Last reviewed · How we verify
Otezla
At a glance
| Generic name | Otezla |
|---|---|
| Sponsor | L.H. Kircik, M.D. |
| Target | cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Behçet's disease affecting oral mucosa
- Plaque psoriasis
- Psoriasis with arthropathy
Common side effects
- Diarrhea
- Nausea
- Headache
- Vomiting
- Upper respiratory tract infection
Serious adverse events
- Severe worsening of psoriasis (rebound)
Key clinical trials
- Human Laboratory Study of Apremilast for Alcohol Use Disorder (PHASE2)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PHASE3)
- Apremilast for Alcohol Use Disorder Treatment in Women and Men (PHASE1)
- Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (PHASE2)
- A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (PHASE3)
- A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |